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ABSTRACT: Multivalent lectin-glycan interactions are wide-
spread in biology and are often exploited by pathogens to bind
and infect host cells. Glycoconjugates can block such interactions
and thereby prevent infection. The inhibition potency strongly
depends on matching the spatial arrangement between the
multivalent binding partners. However, the structural details of
some key lectins remain unknown and different lectins may exhibit
overlapping glycan specificity. This makes it difficult to design a
glycoconjugate that can potently and specifically target a particular
multimeric lectin for therapeutic interventions, especially under the
challenging in vivo conditions. Conventional techniques such as
surface plasmon resonance (SPR) and isothermal titration
calorimetry (ITC) can provide quantitative binding thermody-
namics and kinetics. However, they cannot reveal key structural information, e.g., lectin’s binding site orientation, binding mode, and
interbinding site spacing, which are critical to design specific multivalent inhibitors. Herein we report that gold nanoparticles
(GNPs) displaying a dense layer of simple glycans are powerful mechanistic probes for multivalent lectin-glycan interactions. They
can not only quantify the GNP-glycan-lectin binding affinities via a new fluorescence quenching method, but also reveal drastically
different affinity enhancing mechanisms between two closely related tetrameric lectins, DC-SIGN (simultaneous binding to one
GNP) and DC-SIGNR (intercross-linking with multiple GNPs), via a combined hydrodynamic size and electron microscopy
analysis. Moreover, a new term, potential of assembly formation (PAF), has been proposed to successfully predict the assembly
outcomes based on the binding mode between GNP-glycans and lectins. Finally, the GNP-glycans can potently and completely
inhibit DC-SIGN-mediated augmentation of Ebola virus glycoprotein-driven cell entry (with IC50 values down to 95 pM), but only
partially block DC-SIGNR-mediated virus infection. Our results suggest that the ability of a glycoconjugate to simultaneously block
all binding sites of a target lectin is key to robust inhibition of viral infection.
■ INTRODUCTION
Multivalent lectin-glycan interactions are widespread and
mediate many important biological functions which include
cell-cell communication, pathogen-host cell recognition,
attachment and infection, and modulation of immune
responses.1−9 As most monovalent lectin-glycan binding events
are often too weak to be biofunctional, many lectins form
multimeric structures to cluster their carbohydrate-binding-
domains (CRDs) for efficient binding with spatially matched
multivalent glycans to enhance binding affinity and specific-
ity.10−14 The overall multivalent affinity is not only directly
linked to the monovalent affinity, but also the glycan valency
and the mode of binding. In general, a pair of spatially matched
multivalent binding partners can bind simultaneously with each
other and form a single entity. This gives the highest affinity
enhancement and selectivity due to the most favorable
enthalpy and entropy terms.13 While those without such
spatial and orientation matches may intercross-link with each
other to maximize binding enthalpy and form large scale
assemblies, but this typically gives lower affinity enhancement
and binding specificity due to an unfavorable entropy
penalty.15 Therefore, understanding the structural mechanism
underlying the affinity enhancement in multivalent protein-
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ligand binding is key to the design of potent, specific
multivalent inhibitors against a target multivalent receptor.
Notably, the development of potent glycoconjugates to block
virus binding and infection of host cells can prevent the virus
from mutating and developing resistance, a unique advantage
over other antiviral strategies.9
A number of different scaffolds, including DNAs, proteins,
polymers, dendrimers, C60 derivatives, vesicles, and inorganic
nanoparticles, have been employed to construct glycoconju-
gates14,16−22 to study multivalent lectin-glycan recognition and
develop effective interventions against certain diseases. Some
of these have exhibited excellent potency in inhibiting
pathogen infections.9,11,13,14,16−20,23,24 Most of the bindings
have been evaluated by conventional biophysical techniques
such as surface plasmon resonance (SPR),14,22 and/or
isothermal titration calorimetry (ITC).14,25−27 Despite their
wide use and good capacity in providing quantitative binding
affinity, thermodynamic and kinetic data, these techniques
cannot reveal key structural information on the target lectin,
e.g., binding site orientation, interbinding site distance, and
binding mode which are critical to design potent, specific
multivalent glycan inhibitors. Meanwhile, the unique size-
dependent physical properties of nanomaterials have been
harnessed to study lectin-glycan interactions. A good example
here are gold nanoparticles (GNPs)28 whose strong, size- and
aggregation-state dependent absorption,29,30 powerful signal
amplification in SPR,31 and surface enhanced Raman
scattering32,33 have been widely exploited for biosensing and
diagnostic applications. Despite these successes, glycan
conjugated GNPs (GNP-glycans) have not been exploited as
new structural and mechanistic probes for multivalent lectin-
glycan interactions.
Recently, we have shown that CdSe/ZnS quantum dots
(QDs) displaying a dense layer of mannose glycans are
powerful structural probes for multivalent lectin-glycan bind-
ing.34−36 The QD probes can not only quantify the binding
affinity via a ratiometric FRET readout but also dissect the
different binding modes between a pair of closely related,
almost identical tetrameric lectins, DC-SIGN37,38 and DC-
SIGNR39 (collectively abbreviated as DC-SIGN/R hereafter).
DC-SIGN/R are important lectin receptors which play a key
role in facilitating HIV, Ebola, and Zika viral infec-
tions.34,35,40,41 Moreover, DC-SIGN is also key to immune
regulation,1,5,42,43 making it an highly attractive target for
developing immunotherapies against important human dis-
eases such as cancer, allergy, and autoimmune diseases.1,42,44
However, its tetrameric structure remains unknown, making it
difficult to develop novel glycoconjugates that can potently and
specifically target DC-SIGN for therapeutic interventions,
especially when the overlapping glycan specificity of various
lectins is considered.1 Using the QD-glycans, we have found
that DC-SIGN’s 4 CRDs bind simultaneously to one QD and
give an impressive affinity enhancement factor (β) of up to 1.5
million fold over the corresponding monovalent binding. The
QD-glycans also potently inhibit DC-SIGN-mediated augmen-
tation of Ebola virus entry into host cells with sub-nM IC50
values.35 Despite such success, the cytotoxicity and long-term
toxicity of the CdSe QD scaffold has significantly limited its
potential use as DC-SIGN targeting therapeutic agents,
especially under in vivo conditions.
To address this issue, here we have constructed polyvalent
glycan-nanoparticle probes on a relatively small 5 nm GNP to
take the advantages of GNPs’ excellent biocompatibility, low-/
nontoxicity, and robust gold-thiol surface chemistry for easy
control of the glycan density and surface presentation.28
Moreover, after coating with lipoic acid (LA) based glycan
ligands containing a terminal α-mannose (Man) or α-
mannose-α-1,2-mannose (DiMan), the resulting GNP-glycans
are of the similar size and mannose glycan coating to gp120
trimer,45,46 the HIV surface densely glycosylated glycoprotein
which is responsible for initiating HIV-DC-SIGN interaction
to facilitate HIV infection. The GNP-glycans are thus good
mimics of gp120 for probing its interaction with DC-SIGN.
Furthermore, they also display excellent colloidal stability and
show no signs of aggregation in biologically relevant media,
allowing for unambiguously detection of changes in GNP
aggregation induced by lectin binding. Additionally, as GNP’s
extinction coefficient scales linearly with its volume (Support-
ing Information, SI, Figure S1), the use of a small 5 nm GNP
allows for access to a wide concentration range required for
affinity quantitation (see later section) of weak binders without
introducing significant “inner-filter” effects.
Using DC-SIGN/R as model lectins, we show that the
GNP’s strong fluorescent quenching property47 can be
exploited as a reliable method to quantify multivalent GNP-
glycan-lectin binding for the first time. Moreover, its nanoscale
size, and high contrast under electron microscopy imaging
have been integrated into a multimodal readout to reveal the
different binding modes and affinity enhancement mechanisms
for DC-SIGN/R (e.g., simultaneous binding for DC-SIGN, but
intercross-linking for DC-SIGNR). Furthermore, the GNP-
lectin binding modes are found to be directly linked to the
GNP’s ability to block lectin mediated virus infection of host
cells: only a GNP-glycan which binds simultaneously to all
binding sites of the target lectin can potently and completely
block virus infection, but not that showing a cross-linking
binding mode.
■ RESULTS AND DISCUSSION
Ligand Design and Synthesis. The schematic structures
of the GNP-glycan conjugates and the chemical structures of
the glycan ligands used in this study are shown in Figure 1.
Each ligand contains three unique functional domains, a
dihydrolipoic acid (DHLA) for strong binding to the GNP
surface via the formation of 2 strong Au−S bonds to impose
excellent stability;48 a short, flexible oligo-(ethylene glycol)
linker to enhance water solubility, and to resist nonspecific
adsorption;35,49 and a terminal α-1-mannose or α-1-mannose-
α-1,2-mannose (abbreviated as DHLA-Man or DHLA-DiMan,
respectively, hereafter) for specific binding to DC-SIGN/
R.34,35 We have found previously that DC-SIGN binds more
efficiently to QDs capped with higher mannose densities.34
Moreover, glycoconjugates with higher glycan valency have
often shown to exhibit better virus inhibition poten-
cies.9,14,16,21,50 Thus, we are interested to study whether
GNP-glycans’ DC-SIGN/R binding affinity and virus inhib-
ition potency can be further enhanced by increasing its surface
glycan density. Thus, a branched version of the DHLA-glycan
ligand, each containing three terminal glycans, are also
synthesized (denoted as DHLA-(Man)3 or DHLA-(DiMan)3,
respectively).50 The branched ligands have the same DHLA
anchoring group for GNP binding as the monomeric glycans.
Thus, a similar number of ligands are expected to coat each
GNP, allowing us to prepare more densely glycosylated GNPs
as shown schematically in Figure 1.
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The synthetic routes to the monomeric LA-glycan and
branched trimeric LA-(glycan)3 ligands are shown in Schemes
1 and 2, respectively. First, the LA based linker molecules each
containing one or three terminal acetylene groups were
synthesized in good yields using the standard BOC protection
and amide coupling chemistries. Details of the synthetic
procedures and spectroscopic data of the intermediate
compounds were provided in the SI. Second, α-mannose and
α-mannose-α-1,2-mannose appending a hydrophilic di-
(ethylene glycol)-azide linker (N3-EG2-Man-/DiMan) to
provide some flexibility to the terminal glycans were
synthesized using our established procedures.34,35 Third, the
LA-acetylene linkers were coupled efficiently to N3-EG2-Man/
DiMan via the Cu-catalyzed click chemistry16 to give the
desired LA-Man/DiMan or LA-(Man)3/(DiMan)3 ligands (see
Experimental Section for the general procedures and
spectroscopic data, and SI for their 1H and 13C NMR spectra).
Finally, the LA-glycan ligands were reduced quantitatively to
their corresponding DHLA forms by tris(2-carboxyethyl)-
phosphine hydrochloride (TCEP.HCl)51,52 before they were
used to prepare the GNP-glycans.
GNP-Glycan Preparation. GNP-glycans (GNP capped
with the DHLA-glycan ligands) were prepared by incubation
of a 5 nm citrate stabilized GNP with the above DHLA-glycan
ligands in water at a ligand/GNP molar ratio of 1000:1 for 24
h. Any free unbound ligands were removed by ultrafiltration
using 30K MWCO filter tubes and washing with pure water.
GNP-glycans prepared using LA-glycans or their reduced
DHLA-glycan forms were found to be identical in terms of
hydrodynamic sizes and stability. Thus, the air-stable LA-
glycan ligands could be directly used to make the GNP-
glycans, eliminating the need of reduction and handling air-
sensitive DHLA-glycan ligands that were essential in QD-
glycan preparation via cap-exchange.34,40,48 This made the
GNP-glycan preparation simple and straightforward. This
result was fully consistent with earlier literature reports that
dialkyldisulfides were cleaved upon binding to gold surfaces,
forming identical self-assembled monolayers to their alkylthiol
counterparts.53 The GNP-glycans were highly stable, no
changes of physical appearance or precipitation were observed
after prolonged storage (>6 months) at 4 °C. They were
uniform and monodisperse in both water and in a binding
buffer (20 mM HEPES, 100 mM NaCl, 10 mM CaCl2, pH
7.8) with hydrodynamic diameters (Dhs) of ∼11 nm (see SI
Figure S2 and Table S1). Such Dh values matched well to the
size of gp120 trimer (∼12 nm).45 Moreover, the GNPs were
densely coated with mannose containing glycans similar to
those found on gp120 surface. Using the ligand amount
difference between that used and that remained in the
supernatant after conjugation (measured by a phenol-sulfuric
acid assay),35 the numbers of ligands bound on each GNP
were estimated as ∼490, ∼690, 720, and ∼650 for LA-Man,
Figure 1. Schematic of the GNP-glycans used in this study. The GNP
is coated with DHLA-based glycan ligand containing either one (A)
or three (B) terminal α-1-mannose or α-1-mannose-α-1,2-mannose to
tune its surface glycan valency. The chemical structures of glycan
ligands are depicted underneath.
Scheme 1. Synthetic Route to LA-Man/DiMan Ligands
Scheme 2. Synthetic Route to LA-(Man)3/(DiMan)3
Ligands
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LA-DiMan, LA-(Man)3, and LA-(DiMan)3, respectively. Using
the Dh values and the method reported by the Mirkin group,
54
the average interglycan distances were estimated as ∼0.97,
∼0.83, ∼0.46, and ∼0.49 nm for GNP-Man, GNP-DiMan,
GNP-(Man)3, and GNP-(DiMan)3, respectively (SI Table S2).
The average interglycan distances of GNP-Man/DiMan fell
well within the majority of interglycan sequon distances (e.g.,
0.7−1.3 nm) found on gp120,46 but those of GNP-(Man/
Diman)3 were considerably smaller. These suggested that
GNP-Man/DiMan were good mimics of gp120 for probing its
DC-SIGN interaction.
Quantifying GNP-Glycan-DC-SIGN/R Binding Affinity.
Besides strong plasmonic absorption, GNPs are well-known for
their strong and universal fluorescence quenching property.47
Moreover, its quenching has shown to follow the nanosurface
energy transfer (NSET),55,56 rather than Förster resonance
energy transfer (FRET) mechanism. As a result, its quenching
is more superior and covers a longer distance range than most
organic quenchers relying on the FRET mechanism.47,55
Indeed, the GNP’s superior quenching ability has been widely
exploited for biosensing applications,57,58 but not as a readout
method for lectin-glycan binding quantification. Here the
GNP’s outstanding fluorescence quenching was exploited as a
new readout for multivalent lectin-glycan binding quantifica-
tion for the first time (Figure 2A). To do this, we first
introduced a cysteine site-specifically on the CRD (outside its
glycan binding pocket so not affecting its glycan binding
properties) of DC-SIGN/R extracellular segments by muta-
genesis. The mutant proteins have shown to retain faithfully
the tetrameric structure and glycan binding properties of
wildtype proteins.34,35 We then labeled the proteins using a
maleimide modified Atto-594 and confirmed the labeling by
high resolution mass spectroscopy (SI Figure S3). We then
recorded the fluorescence spectra of labeled DC-SIGN/R
without and with each GNP-glycan under a fixed protein:GNP
molar ratio of 1:1 over a concentration range of 0−64 nM. All
binding studies were carried out in a binding buffer containing
a large excess of bovine serum albumin (BSA, 1 mg/mL final
concentration). The inclusion of large excesses of BSA, a
nontarget serum protein of high abundance in vivo, in binding
studies made the conditions resemble more closely to real
biological situations. Moreover, this also greatly reduced
nonspecific interactions and adsorption of proteins and
GNPs to surfaces (a main source of experimental errors at
low concentrations, e.g., < 10 nM).59
The typical fluorescence spectra showing the binding
between DC-SIGN and GNP-DiMan were given in Figure
2B. In the absence of GNP-DiMan, DC-SIGN’s fluorescence
intensity was found to increase linearly with concentration.
While in the presence of GNP-DiMan, its fluorescence was
greatly reduced and increasingly deviated from the linear
relationship with the increasing concentration (SI Figure S4).
This result was fully consistent with that, with the increasing
concentration, an increasing proportion of DC-SIGN were
bound to and quenched by GNP-DiMan in close proximity.
The specificity of DC-SIGN-GNP-DiMan binding was verified
by two controls: (1) mixing DC-SIGN with a GNP capped
with a control DHLA-EG2-OH ligand lacking the terminal
glycan produced negligible quenching; (2) free mannose could
effectively compete with GNP-DiMan binding to DC-SIGN,
leading to a significant, dose-dependent fluorescence recovery
(SI Figure S5).
To analyze the binding data quantitatively, we first
calculated the quenching efficiency (QE) at each concentration
(C) via:
= − ×QE% (IF IF)/IF 100%0 0 (1)
where IF0 and IF are the integrated fluorescence of the protein
in the absence and presence of each GNP-glycan, respectively.
Given that the fluorescence of DC-SIGN/R increases linearly
with C in the absence of GNP-DiMan (SI Figure S4), and
GNPs can completely quench various fluorophores at close
proximity (e.g., > 99.9%),47 the QE% thus faithfully represents
the percentage of proteins bound to the GNP-glycan. Thus,
the apparent binding dissociation constant (Kd) can be derived
from the QE-C relationship by fitting with Hill’s equation:
= × +C K CQE QE /( )n n nmax d (2)
where QEmax, Kd, C, and n are the maximum QE (fixed at 100),
apparent binding dissociation constant, protein concentration,
and Hill coefficient, respectively.
Figure 2C,D showed the best fits of the QE-C relationships
for DC-SIGN/R binding to each GNP-glycan. The resulting
fitting parameters were summarized in Table 1. Four key
points could be drawn from the binding data given in Table 1.
(1) DC-SIGN bound more strongly to GNP-glycans than DC-
SIGNR did. This effect was particularly pronounced for GNP-
DiMan where the binding affinity difference was as high as ∼40
fold. As GNP-DiMan here presented a good mimic of gp120,
its stronger binding affinity with DC-SIGN over DC-SIGNR
could thus help to explain why DC-SIGN was found to be
more effective than DC-SIGNR in transmitting infections for
some HIV strains.60 This result also agreed well with those
reported previously with QD-glycans where the binding Kds
were measured ratiometrically via FRET.34 Given that the
CRDs in DC-SIGN/R had the same mannose binding
motifs,61 the difference here indicated that the DC-SIGN/R
Figure 2. (A) Schematic showing the quenching of DC-SIGN/R
(dye-labeled) fluorescence upon binding to a GNP-glycan, which acts
as a readout for binding quantification. (B) Typical fluorescence
spectra of varied concentrations of DC-SIGN without (solid lines)
and with (broken lines) 1 mol equiv of GNP-DiMan (λEX = 590 nm).
(C, D) The quenching efficiency (QE%)-concentration relationship
for DC-SIGN (C) or DC-SIGNR (D) binding to the various GNP-
glycans fitted by the Hill’s equation.
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might adopt different modes in binding to GNP-glycans,
similar to those observed with QD-glycans.35 (2) Further
increasing the GNP surface glycan density via capping with the
dendritic LA-(glycan)3 ligands significantly improved the
binding affinity with DC-SIGNR (e.g., Kd ≈ 42 vs ≈ 152
nM, or 3.6-fold enhancement for GNP-(DiMan)3 vs GNP-
DiMan), but not much with DC-SIGN, suggesting that DC-
SIGNR may prefer binding to GNPs with even higher glycan
densities. (3) Low nM Kd (e.g., 3.9 nM) for DC-SIGN binding
with GNP-DiMan was obtained, which was ∼250 000-fold
tighter than the corresponding monomeric binding between
DiMan and DC-SIGN CRD (Kd = 0.9 mM),
25 suggesting that
a polyvalent display of the glycans on the GNP greatly
enhanced its multivalent binding affinity with DC-SIGN.
These results were fully consistent with those reported for
other multivalent lectin-glycoconjuagte interactions.10,14,18,22
(4) A higher degree of affinity enhancement was observed for
DC-SIGN binding to GNP-DiMan over GNP-Man, possibily
due to the former being able to exploit the CRD’s secondary
glycan binding sites more efficiently than the latter.61 Overall,
these results agreed well with those reported previously with
the QD-glycans.35
Probing DC-SIGN/R-GNP-Glycan Binding Mode and
Affinity Enhancing Mechanism. First we monitored the Dhs
of GNP-DiMan before and after binding to wild-type DC-
SIGN/R (unlabeled) by dynamic light scattering (DLS).62
GNP-DiMan displayed a single Dh species of ∼11 nm with a
narrow distribution (full width at half-maximum, fwhm = 3.5
nm, Figure 3A1) in the binding buffer. After mixing with DC-
SIGN (protein/GNP molar ratio = 20:1), the size of the
dominate species was significantly increased (Dh ≈ 41 nm) and
broadened (fwhm ≈ 28 nm, Figure 3A2). This result was
consistent with that expected for each GNP-glycan being
Table 1. Summary of the Fitting Parameters of DC-SIGN/R
Binding to Various GNP-Glycans Derived from Figure 2C,D
GNP-glycan + protein Kd (nM) n R
2
GNP-Man + DC-SIGN 33.1 ± 2.1 0.82 ± 0.07 0.997
GNP-(Man)3 + DC-SIGN 18.7 ± 0.3 0.77 ± 0.01 0.999
GNP-DiMan + DC-SIGN 3.9 ± 0.3 0.59 ± 0.03 0.999
GNP-(DiMan)3 + DC-SIGN 3.6 ± 0.1 0.42 ± 0.01 1.00
GNP-Man + DC-SIGNR 214 ± 68 0.68 ± 0.10 0.994
GNP-(Man)3 + DC-SIGNR 133 ± 20 0.63 ± 0.07 0.996
GNP-DiMan + DC-SIGNR 152 ± 37 0.99 ± 0.14 0.954
GNP-(DiMan)3 + DC-SIGNR 42 ± 2 0.48 ± 0.03 0.999
Figure 3. Typical Dh distribution histograms of GNP-DiMan only (10 nM, A1); GNP-DiMan (10 nM) + wild-type DC-SIGN (200 nM, A2); or
GNP-DiMan (16 nM) + wild-type DC-SIGNR (640 nM, A3). TEM images of cryo-prepared samples of GNP-DiMan only (40 nM, B1), GNP-
DiMan (40 nM) + DC-SIGN (1.5 μM, B2) or GNP-DiMan (40 nM) + DC-SIGNR (1.5 μM, B3), and their corresponding GNP nearest neighbor
distance (NND) histograms (C1, C2, C3). The red curves show the Guanssian fits of the histograms.
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bound by a limited number of DC-SIGN molecules, forming a
protein shell on the GNP. In contrast, mixing DC-SIGNR with
GNP-DiMan produced a dominant species whose Dh was
gradually increased from ca. 300 to >2000 nm over a period of
4 h (Figure 3A3). Such sizes were clearly too big to be
individual GNP-DC-SIGNR assemblies, a strong indication of
macroscopic assembly, arising presumably from DC-SIGNR
and GNP-DiMan intercross-linking.
This assumption was verified by transmission electron
microscopy (TEM) imaging of cryo-prepared GNP-DiMan-
protein samples via rapid plunge freezing followed by vacuum
drying which we had shown previously to preserve the native
dispersion states of nanoparticle solutions (SI Figure S6).63 In
the absence of DC-SIGN/R, GNP-DiMan appeared as isolated
single particles (Figure 3B1) and gave a randomly distributed
nearest neighbor distance (NND) over a range of 10 to 100
nm (Figure 3C1). Binding of DC-SIGN with GNP-DiMan also
gave isolated single particles (Figure 3B2), although the
resulting NND distribution histogram could be fitted well (R2
= 0.982) by a single Gaussian distribution to yield an average
NND of ∼44 nm (Figure 3C2). Interestingly, this NND value
matched well to the Dh size of GNP-DiMan-DC-SIGN
assembly (∼41 nm), suggesting that the formation of a layer
of DC-SIGN on the GNP prevented individual GNPs from
coming close to each other. In contrast, binding of DC-SIGNR
with GNP-DiMan produced large scale, closely packed GNP
assemblies of hundreds of nm cross (Figure 3B2) with a rather
small NND of ∼7.9 nm (Figure 3C3). This result agreed well
with the DLS measurement, confirming that binding of DC-
SIGNR led to macroscopic assemblies of GNPs via DC-
SIGNR-GNP-DiMan intercross linking. These results revealed
that the binding modes of DC-SIGN/R to GNP-DiMan were
clearly different: DC-SIGN must have bound simultaneously to
one GNP-DiMan via all of its four binding sites and formed a
layer of proteins surrounding each GNP, giving rise to isolated
single particles. In contrast, DC-SIGNR and polyvalent GNP-
DiMan intercross-linked each other, and formed large scale but
closely packed GNP-DC-SIGNR assemblies. Therefore, by
harnessing GNPs’ nanoscale size and high contrast under TEM
imaging, we have developed a new multimodal readout which
successfully dissected the distinct modes of GNP-DiMan in
binding to DC-SIGN/R. This result agreed fully with those
reported previously with QD-glycans.35
The distinct binding modes exhibited by DC-SIGN/R could
also help explain their different affinities with GNP-glycans.
For DC-SIGN, its simultaneous binding with one GNP via all
4 of its CRDs should yield strong affinity enhancement from
both the favorable enthalpy and entropy terms. For DC-
SIGNR, while its intercross-linking mode of binding with
GNP-glycans could maximize the binding enthalpy, the
resulting large scale assemblies would incur significant entropy
penalty. As a result, DC-SIGN should bind more strongly to
GNP-glycans than DC-SIGNR did, matching well to the
apparent Kd data measured by fluorescence quenching (Table
1).
Correlation between Lectin-GNP-Glycan Affinity and
Assembly. The credibility of this GNP quenching based
affinity measurement method was further verified by the DLS
data. For example, binding of an increasing amount of DC-
SIGN to a fixed amount of GNP-DiMan (10 nM) gave a more
rapid increase of Dh than that to GNP-Man (Figure 4A),
consistent with the former being a stronger binding partner
than the latter (apparent Kd: 3.9 vs 33 nM). Moreover, mixing
an increasing amount of DC-SIGNR with GNP-(Man)3
yielded no noticeable Dh changes throughout the concen-
tration range studied (20−200 nM), indicating no measurable
binding (Figure 4B). While mixing DC-SIGNR with GNP-
(DiMan)3 also produced no apparent Dh changes initially
(≤100 nM); as DC-SIGNR concentration was increased
further, a dramatic increase of Dh was observed, particularly at
200 nM, a clear indication of the formation of large scale GNP-
DC-SIGNR assemblies (see Figure 4B, and SI Figures S7−
S10).
To provide a more quantitative explanation of the data, here
we introduced a new term: the potential of assembly formation
(PAF):
= ×C C KPAF /( )0(GNP) 0(protein) d
2
(3)
where C0(GNP), C0(protein), and Kd are GNP-glycan and protein
starting concentrations and their apparent binding Kd,
respectively. As Kd indicates 50% binding at equilibrium, the
PAF thus represents the ratio of a reaction quotient to
equilibrium of a reversible binding reaction. Where PAF = 1
would indicate equilibrium (50%) binding, while PAF > 1
indicates binding being favorable and PAF > 10 being strongly
favorable (>90%). Similarly, PAF < 1 indicates binding being
unfavorable and PAF < 0.1 being strong unfavorable (<10%
binding).
Using this definition and the apparent Kds given in Table 1,
the PAFs for DC-SIGN binding to GNP-Man and GNP-
DiMan were in the range of 0.18−1.8, and 13−131,
respectively. While those for DC-SIGNR binding to GNP-
(Man)3 and GNP-(DiMan)3 ranged from 0.011 to 0.11, and
0.11 to 1.1. Combining the PAF value and binding mode
would allow us to predict the assembly outcome. For example,
with a PAF of >10 and simultaneous binding, most of the
added DC-SIGN molecules should readily bind to GNP-
DiMan to saturate its surface binding capacity, giving rise to a
rapidly increasing and quickly saturated Dh with the increasing
protein concentration. This was exactly what was measured
from DLS. In contrast, the PAF of DC-SIGN-GNP-Man
binding span across 1, which would indicate a gradually
increased binding, again matching well to a positive, linear Dh-
concentration relationship (Figure 4A). For intercross-linking
binding between DC-SIGNR and GNP-glycans, large-scale
assemblies were only observed for GNP-(DiMan)3 mixed with
Figure 4. Dh-Cprotein relationships for GNP-glycan (10 nM) binding to
wild-type DC-SIGN/R at different concentrations. (A) DC-SIGN
binding to GNP-DiMan (black squares, fitted by Hill’s equation: Y =
a + (b − a) × Xn/(kn + Xn); where a = 11.1 ± 0 nm; b = 80 ± 99 nm;
k = 200 ± 990 nM; and n = 0.53 ± 0.36, R2 = 0.997) or GNP-Man
(red dots, fitted by a linear relationship, Y = a + b × X; where a = 11.6
± 0.7 nm; b = 0.091 ± 0.010, R2 = 0.928); and (B) DC-SIGNR
binding to GNP-(DiMan)3 (blue triangles) or GNP-(Man)3 (green
triangles).
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the highest protein concentration (200 nM) which had a PAF
of 1.1 and indicated the binding became favorable. While all
other conditions where PAFs were <1, no significant binding
(assembly) was observed (Figure 4B). Together, these results
established PAF as a useful indicator for predicting the binding
(assembly) outcome of multivalent lectin-glycan binding
partners. Furthermore, the excellent agreement between the
predicted outcome based on PAFs (derived from Kds measured
via the GNP quenching method) and those observed from
DLS implied that this new fluorescence quenching based
binding affinity method was highly credible and reliable.
Interestingly, the ability of lectins to bind and intercross-link
with viral surface glycoproteins has been shown to play an
important role in viral neutralization.64−66 Thus, we anticipate
that the PAF criteria proposed here could act as a useful tool to
predict lectin-virus interactions and neutralization.
Blocking DC-SIGN/R-Mediated Augmentation of
Ebola Virus Glycoprotein-Driven Transduction. The
distinct binding modes and affinities of GNP-glycans with
two important viral receptors, DC-SIGN/R, should result in
different abilities in blocking DC-SIGN/R-mediated virus
infection of host cells. To investigate this potential and any
possible correlation, human embryonic kidney 293T cells
transfected to express DC-SIGN or DC-SIGNR on their
membrane were used as previously described.35 Murine
leukemia virus (MLV) vector particles bearing the Ebola
virus surface glycoprotein (EBOV-GP) and encoding the
luciferase gene were used to model Ebola virus entry into cells.
The virus particles can bind efficiently to DC-SIGN/R (via
their surface EBOV-GP) and binding results in increased
transduction as determined by luciferase expression in host
cells.34,35 Binding of high affinity GNP-glycans to host cell
surface DC-SIGN/R could block these lectin receptors from
further binding to EBOV-GP, thereby reducing luciferase gene
transduction. Indeed, pretreatment of 293T cells with GNP-
glycans efficiently inhibited DC-SIGN-mediated augmentation
Table 2. Summary of Inhibition Data for GNP-Glycans against DC-SIGN/R-Mediated EBOV-GP Driven Infection of 293T
Host Cells
GNP-glycan receptor IC/EC50 (nM) n R
2
GNP-Man DC-SIGN 0.26 ± 0.08 1 0.889
GNP-(Man)3 DC-SIGN 1.57 ± 0.25 1 0.937
GNP-DiMan DC-SIGN 0.095 ± 0.017 1 0.921
GNP-(DiMan)3 DC-SIGN 0.15 ± 0.03 1 0.890
GNP-Man DC-SIGNR 7.3 ± 1.2a 0.42 ± 0.04 0.980
GNP-(Man)3 DC-SIGNR 53 ± 17
a 0.61 ± 0.14 0.902
GNP-DiMan DC-SIGNR 0.63 ± 0.09a 0.56 ± 0.02 0.990
GNP-(DiMan)3 DC-SIGNR 2.6 ± 0.1
a 0.53 ± 0.02 0.997
aShows the EC50 values for DC-SIGNR.
Figure 5. Plot of normalized luciferase activities of DC-SIGN- or DC-SIGNR- expressing 293T cells as a function of the concentration of GNP-
DiMan (A) or GNP-(DiMan)3 (B) inhibitors. Data for virus particles bearing the EBOV-GP are shown in dots while those of control virus particles
bearing the VSV-G are shown in triangles. Schematics beneath showing the different inhibition efficiencies of GNP-glycans against DC-SIGN (C)
or DC-SIGNR (D) mediated infections. (C) For DC-SIGN expressing host cells, all of the binding sites of its surface DC-SIGNs are bound and
blocked by GNP-glycans, making them unavailable for further binding to virus surface EBOV-GPs to initiate infection. (D) For DC-SIGNR
expressing host cells, GNP-glycans cross-link with some surface DC-SIGNRs but the bindings are weak and dynamic at the edges, allowing the virus
to access the unblocked DC-SIGNR binding sites to initiate infection.
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of transduction in a dose-dependent manner (SI Figure S11).
GNP-DiMan/-(DiMan)3 were found to be more potent in
blocking the transduction than GNP-Man/-(Man)3. This
result was consistent with the former being stronger DC-
SIGN binders than the latter. The normalized dose-dependent
inhibition data were fitted well by a simple competition model:
= [ + ]CNA IC / IC50 50 (4)
where NA, IC50, and C were normalized luciferase activity,
GNP concentration giving 50% inhibition, and GNP
concentration, respectively. While DC-SIGNR-mediated aug-
mentation of gene transduction was also inhibited by GNP-
glycans, the resulting normalized dose-dependent inhibition
data were best fitted by a modified competition model:
= [ + ]CNA EC / ECn n n50 50 (5)
where the inhibition coefficient, n, was found to be in the range
of 0.4 to 0.6 (Table 2), indicating a poor inhibition efficiency.
Moreover, GNP-glycans could not completely inhibit DC-
SIGNR-mediated transduction, even at high concentrations
(see Figures 5A/B, and S12). This result revealed that GNP-
glycans were much less effective in blocking DC-SIGNR-
mediated augmentation of gene transduction than that of DC-
SIGN-dependent transduction.
We believe this result is reasonable from both the binding
affinity (GNP-glycans bind more weakly to DC-SIGNR than to
DC-SIGN) and binding mode points of view. Each GNP-
glycan could bind simultaneously to all 4 of DC-SIGN’s
binding sites, completely blocking them from further binding
to virus surface EBOV-GPs to initiate cell entry (Figure 5C).
In contrast, the intercross-linking mode of binding between
GNP-glycans and DC-SIGNR meant that each GNP could
only bind to 2 of the 4 binding sites in DC-SIGNR. It would be
very difficult for GNP-glycans to cross-link all cell surface DC-
SIGNRs to fully block their binding sites. Even if this was
possible, the DC-SIGNRs at the cluster edge would still only
bind divalently (via 2 outward facing binding sites) to GNP-
glycans, where the binding would be weak and dynamic. These,
together with any unbound binding sites, could act as toe-holds
for binding to viral surface EBOV-GPs to initiate cell uptake
and infection (Figure 5D). Therefore, an inhibitor that
intercross-links with target receptors would be much less
effective in blocking virus infection than its simultaneous
binding counterpart, making it almost impossible to achieve
complete inhibition (Figure 5C/D). This effect was clearly
demonstrated from a side-by-side comparison of virus
inhibition data for two GNP-glycan-lectin pairs showing
similar affinity but with distinct binding modes, e.g., GNP-
Man-DC-SIGN (Kd: 33 ± 2 nM) vs GNP-(DiMan)3-DC-
SIGNR (Kd: 42 ± 2 nM). The simultaneous binding pair
(GNP-Man-DC-SIGN) clearly displayed higher inhibiting
potencies over its cross-linking counterpart (GNP-(DiMan)3-
DC-SIGNR) across the whole range of concentrations studied
(SI Figure S13A), even on a Kd normalized concentration (C/
Kd) term to eliminate the effect of small Kd differences (SI
Figure S13B). The difference was even clearer by comparing
the relative infection ratio between the cross-linking and
simultaneous binding pairs where a stable ratio of ∼1.6 was
observed at low GNP concentrations (≤3 nM, or ≤1/10 of
Kds). As concentration was increased, comparable to the Kds,
the ratio was increased markedly and reached ∼27 at 50 nM
(SI Figure S13C). The observation that the potency difference
for GNP inhibitors of different binding modes was more
pronounced at high concentrations where most cell surface
lectins would be blocked by GNPs, matched well to what was
expected from our proposed mechanism above.
Besides, comparing the GNP-lectin binding affinity (Table
1) and inhibition potency (Table 2) data revealed that the Kd
and IC50/EC50 values did not always follow the expected
positive correlation (e.g., stronger binders being better
inhibitors), even for those showing the same binding mode.
The Kd−IC50 relationship appeared to be affected by GNP
surface glycan density. A positive Kd−IC50 correlation was only
observed for GNPs having similar glycan densities (e.g., GNP-
Man vs GNP-DiMan, or GNP-(Man)3 vs GNP-(DiMan)3),
but not for those having large glycan density differences (e.g.,
GNP-Man vs GNP-(Man)3 or GNP-DiMan vs GNP-
(DiMan)3). The latter gave an unexpected negative Kd−IC50
correlation (e.g., stronger binders being worse inhibitors),
possibly caused by the different binding environments used in
GNP-lectin binding and virus inhibition studies. The former
was performed in solution, where both the GNPs and lectins
were free to move in all three dimensions, allowing them to
easily adjust their relative positions to maximize binding.
Under such conditions, it appeared that a high glycan density
on GNP surface was beneficial for lectin binding. Whereas in
virus inhibition studies, all valid bindings (capable of blocking
virus binding) could only take place on two-dimensions with
cell membrane bonded lectins. The binding partners,
particularly cell surface lectins, would exhibit greatly reduced
freedom of movement which might have led to a different
glycan density for optimal binding (and hence virus
inhibition).
Importantly, luciferase activities of control virus particles
bearing the vesicular stomatitis virus glycoprotein (VSV-G),
which cannot use DC-SIGN/R for augmentation of cell entry,
were not affected significantly by GNP-glycan treatment,
confirming that the observed inhibitory effects were specific
(SI Figure S11). It was noteworthy to point out that the IC50
value of GNP-DiMan in blocking DC-SIGN-mediated
augmentation of EBOV-GP-dependent entry was measured
as 0.095 ± 0.017 nM. This value was considerably lower (by
almost an order of magnitude) than those measured for some
of the most potent glycoconjugate inhibitors of Ebola virus
infection reported previously (e.g., the giant globular multi-
valent glycofullerenes, IC50: 0.67 nM,
21 the virus-like
glycodendrinanoparticles, IC50: 0.91 nM,
16 and our previous
QD-EG3-DiMan, IC50: 0.70 ± 0.2 nM).
35 This result
demonstrated an outstanding potency of the GNP-glycans in
blocking DC-SIGN-mediated EBOV-GP driven infection of
host cells. Importantly, as viral surface glycans are maintained
by the host cell’s glycosylation apparatus, they are mostly
conserved and unaffected by virus mutation.67 Therefore, the
potential advantages of developing potent glycoconjugate viral
inhibitors over other antiviral strategies are twofold: (1) it can
reduce the chances of virus mutation by blocking its entry to
host cells, and (2) its treatment potency is unlikely affected by
virus mutation, allowing us to provide a potentially long lasting
solution.
■ CONCLUSIONS
In summary, we have developed polyvalent GNP-glycans as
new powerful structural and mechanistic probes for multivalent
lectin-glycan interactions. By exploiting GNPs’ outstanding
fluorescence quenching property, we have developed a new
method for quantifying multivalent lectin-glycan interaction,
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revealing that a polyvalent display of mannose containing
glycans on GNPs greatly enhances their binding affinities with
two vitally important viral receptors, DC-SIGN/R. Moreover,
by exploiting GNPs’ nanoscale size and high TEM contrast, we
have revealed the distinct binding mode and affinity enhancing
mechanisms for GNP-glycans binding with DC-SIGN/R.
Importantly, the assembly outcomes of the dose-dependent
GNP-lectin binding are in perfect agreement with those
predicted from their respective binding modes and affinities,
verifying the credibility of our new affinity method.
Furthermore, we have found that GNP-glycans can potently
block DC-SIGN-mediated EBOV-GP driven viral infections of
host cells with IC50 values down to 95 ± 17 pM, making it the
most potent glycoconjugate inhibitor against EBOV-GP driven
infection. Notably, its inhibition potency will unlikely be
affected by virus mutation, allowing us to provide potentially a
long lasting solution. Finally, we have revealed that only a
GNP-glycan inhibitor showing a simultaneous-, but not a
cross-linking-, binding mode is able to completely block the
target lectin mediated virus infection. Together, these data
provide a useful guidance in designing polyvalent glycoconju-
gates for potent, specific inhibition of virus infection. Given
their low-/non-toxicity and excellent biocompatibility, the
GNP-glycans are perfectly placed for a wide range of
applications, from probing fundamental structural mechanisms
of glycobiology, developing novel biophysical and biomedical
assays, to developing novel therapeutics against deadly virus
infections and immune dysregulation diseases such as cancer,
allergies, and autoimmune diseases.
■ EXPERIMENTAL SECTION
Materials. Gold nanoparticle (nominal diameter 5 nm, λmax ≈ 520
nm) was purchased from Sigma-Aldrich as a stabilized suspension in
citrate buffer or synthesized in house. 2-(2-Aminoethoxy)-ethanol, di-
tert-butyl decarbonate, sodium sulfate, sodium hydride (60%
dispersion in mineral oil), 3-bromo-1-propyne, potassium hydroxide,
trifluoroacetic acid, triethylamine, sodium bicarbonate, O-(6-chlor-
obenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexa fluorophos-
phate (HCTU), lipoic acid (LA), tris(2-carboxyethyl) phosphine
hydrochloride (TCEP.HCl), copper sulfate, sodium ascorbate,
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA), tris-
(hydroxymethyl)aminomethane (Tris base), guanidine hydrochloride,
anhydrous DMF, and other chemicals were purchased from Sigma-
Aldrich, Alfa Aesar, Fluorochem, Thermo Scientific, VWR Interna-
tional, or Acros organics with >99% impurity and used as-received
without further purification unless specified elsewhere. All the solvents
were obtained in >99% purity from Fischer Scientific and used as-
received. When used as reaction solvents in anhydrous reactions, THF
and CH2Cl2 were dried and deoxygenated using an Innovative
Technology Inc. PureSolv solvent purification system. Ultrapure water
(resistance >18.2 MΩ·cm) purified by an ELGA Purelab classic UVF
system, was used for all experiments and making buffers.59,62
Glycan-Ligand Synthesis by Click Chemistry. The general
protocols employed in preparing the LA-glycan ligands via click
chemistry were as follows.16 To a 1:1 (v:v) mixed THF:H2O solution
(2.0−5.0 mL) containing the glycan-EG2-N3 (1.1 mol equiv) and LA-
linker (1 mol equiv) were added CuSO4·5H2O (0.036 mol equiv),
TBTA (0.063 mol equiv) followed by sodium ascorbate (0.135 mol
equiv) and the resulting solution was stirred at RT. After 3 h, TLC
confirmed the consumption of all starting materials. The solvent was
then evaporated and the crude product was purified by size exclusion
chromatography using Biogel P2 column using water as eluent to
afford the desired pure LA-glycan product.
LA-Man. Yield = (67%, 0.18 mmol). 1H NMR (500 MHz,
CD3OD) δ (ppm): 8.04 (s, 1H, triazole-H), 4.8 (d, 1H, J 1.6 Hz, Man
H-1), 4.65 (s, 2H), 4.6 (t, 2H, J 5 Hz), 3.9 (t, 2H, J 5.1 Hz), 3.86−
3.81 (m, 3H), 3.8 (dd, 1H, J 1.7 Hz, 3.4 Hz, Man H-2), 3.72 (d, 1H, J
5.5 Hz), 3.69−3.67 (m, 3H), 3.66 (s, 2H), 3.65−3.63 (m, 2H), 3.62−
3.61 (m, 4H), 3.60−3.57 (m, 2H), 3.53 (t, 2H, J 5.5 Hz), 3.39−3.34
(m, 3H), 3.20−3.15 (m, 1H), 3.12−3.07 (m, 1H), 2.49−2.42 (m,
1H), 2.20 (t, 2H, J 7.4 Hz), 1.92−1.85 (m, 1H), 1.73−1.59 (m, 4H),
1.50−1.40 (m, 2H). 13C NMR (125 MHz, CD3OD) δ: 176.1 (C
O), 145.7 (CCH), 126.0 (CCH), 101.7 (Man C-1), 74.6, 72.6,
72.1 (Man C-2), 71.6, 71.5, 71.4, 71.3, 70.8, 70.6, 70.4, 68.6, 67.7,
65.0, 63.0 (Man C-6), 57.6, 51.5, 41.3, 40.3, 39.3, 36.8, 35.7, 29.8,
26.7. HRMS: calculated m/z for C27H49N4O11S2 (M+H)
+ 669.2834;
found 669.2838.
LA-DiMan. Yield = (65%, 0.080 mmol). 1H NMR (500 MHz,
CD3OD) δ (ppm): 8.05 (s, 1H, triazole-H), 5.11 (d, J 1.7 Hz, 1H),
4.96 (d, J 1.8 Hz, 1H), 4.66 (s, 2H), 4.60 (t, 2H, J 5.1 Hz), 3.97 (dd,
1H, J 3.3, 1.8 Hz), 3.91 (dd, 2H, J 5.5, 4.7 Hz), 3.88−3.78 (m, 6H),
3.72−3.65 (m, 8H), 3.62 (dt, 6H, J 5.0, 1.3 Hz), 3.58 (dt, 3H, J 11.2,
1.6 Hz), 3.53 (t, 2H, J 5.5 Hz), 3.43−3.32 (m, 3H), 3.17 (ddd, 1H, J
10.9, 7.1, 5.4 Hz), 3.10 (dt, 1H, J 11.0, 6.9 Hz, 1H), 2.46 (dtd, 1H, J
12.1, 6.7, 5.4 Hz), 2.20 (t, 2H, J 7.4 Hz), 1.89 (dq, 1H, J 12.7, 6.9
Hz), 1.77−1.57 (m, 4H), 1.45 (qt, 2H, J 9.4, 5.9 Hz). 13C NMR (125
MHz, CD3OD) δ: 176.1 (CO), 145.7 (CCH), 126.0 (CCH),
104.2 (Man C-1), 100.1 (Man C-1′), 80.6, 75.1, 74.7, 72.4, 72.1, 71.9,
71.6, 71.5, 71.4, 71.3, 70.8, 70.6, 70.5, 69.0, 68.8, 67.9, 65.0, 63.2,
63.1, 57.6, 51.5, 41.3, 40.4, 39.3, 36.8, 35.7, 29.8, 26.7. HRMS:
calculated m/z for C33H58N4O16S2 (M+H)
+ 831.3233; found
831.3242.
LA-(Man)3. Yield = (60%, 0.060 mmol).
1H NMR (500 MHz,
D2O) δ (ppm): 8.03 (s, 3H, triazole-H), 4.87 (d, 3H, J 1.8 Hz, H-1),
4.64−4.61 (m, 6H), 4.60 (s, 6H), 3.98−3.96 (m, 6H), 3.95 (dd, 3H, J
3.5, 1.8 Hz, H-2), 3.89 (d, 1H, J 2.0 Hz), 3.87 (d, 2H, J 1.7 Hz),
3.84−3.79 (m, 6H), 3.77 (d, 2H, J 5.6 Hz), 3.74 (d, 7H, J 3.1 Hz),
3.67 (d, 3H, J 9.8 Hz), 3.65−3.61 (m, 25H), 3.61−3.53 (m, 3H),
3.21−3.12 (m, 2H), 2.42 (dq, 1H, J 12.3, 6.1 Hz), 2.18 (t, 2H, J 7.0
Hz), 1.91 (dt, 1H, J 13.6, 6.8 Hz), 1.71−1.64 (m, 1H), 1.58−1.48 (m,
4H), 1.33 (q, 3H, J 7.7 Hz). 13C NMR (125 MHz, D2O) δ: 176.5
(CO), 144.0, 125.3, 99.9 (C-1), 72.7, 70.5, 69.9, 69.5, 69.4, 68.8,
67.5, 66.7, 66.3, 63.5, 60.9, 59.7, 56.5, 50.0, 40.2, 38.0, 35.9, 33.7,
27.5, 24.9. HRMS: calculated m/z for C57H99N10O28S2 (M+H)
+
1435.6066; found 1435.6096.
LA-(DiMan)3. Yield = (69%, 0.030 mmol).
1H NMR (500 MHz,
D2O) δ (ppm): 8.03 (s, 3H, triazole-H), 5.11 (d, 3H, J 1.8 Hz, H-1),
5.03 (d, 3H, J = 1.9 Hz, H-1′), 4.64−4.62 (m, 6H), 4.60 (d, 6H, J 2.9
Hz), 4.08 (dd, 3H, J 3.4, 1.8 Hz, H-2), 3.97 (td, 9H, J = 4.5, 2.5 Hz),
3.92−3.68 (m, 40H), 3.66−3.61 (m, 29H), 3.58−3.53 (m, 3H),
3.21−3.13 (m, 2H), 2.42 (dq, 1H, J 12.3, 6.1 Hz), 2.18 (t, 2H, J 7.0
Hz), 1.91 (dd, 1H, J 13.1, 6.8 Hz), 1.67 (m, 1H), 1.59−1.49 (m, 4H),
1.32 (p, 3H, J 7.7 Hz).). 13C NMR (125 MHz, D2O) δ: 179.0 (C
O), 146.5, 127.9, 104.8 (C-1), 100.9 (C-2), 81.2, 75.8, 75.3, 74.2,
72.8, 72.7, 72.5, 72.2, 72.0 (2), 71.9, 71.3 (2), 70.1, 69.4 (2), 69.0,
66.1, 63.7, 63.4, 62.9, 62.3, 59.0, 52.6, 42.8, 40.6, 38.4, 36.2, 30.1,
27.4. HRMS: calculated m/z for C75H130N10O43S2 (M+H)
2+
961.3862; found 961.3858.
GNP-Glycan Preparation. Ten mL of 5 nm GNP stock was
concentrated to 250 μL using a 30 kDa MWCO spin column and
washed with H2O (3 × 200 μL) to remove any impurities. Then
DHLA-glycan ligands dissolved in H2O were added to the GNP
solution in a molar ratio of GNP/DHLA-glycan = 1:1000. The
resulting solution was mixed and stirred at RT in dark for overnight.
The resulting mixture was passed through a 30 kDa MWCO spin
column by centrifugation at 15 000g for 2 min and the residues were
washed with H2O (3 × 200 μL) to give the GNP-glycan stock. The
filtrate and washing through liquids were combined and used to
evaluate the glycan loading on GNPs as described previously.34 The
concentration of the GNP-glycans was determined from its
absorbance at 520 nm using the Beer−Lambert law and a GNP
molar extinction coefficient of 1.1 × 107 M−1·cm−1.
Protein Production and Labeling. The soluble extracellular
segments of DC-SIGN (DC020) and DC-SIGNR (DSR034) were
expressed as inclusion bodies in E. coli and purified by Man-Sepharose
affinity column followed by Superdex size exclusion column as
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reported previously.34 The mutant proteins, DC020 Q-274C and
DSR034 R278C, were constructed by site directed mutagenesis and
labeled with atto594-maleimide as described previously.35,40 The
labeled proteins were purified by mannose-Sepharose affinity column.
All the proteins obtained were characterized by high resolution mass
spectroscopy (HRMS), and their corresponding spectra were shown
in SI Figure S3. The dye labeling efficiency (per protein monomer)
for DC-SIGN and DC-SIGNR was determined to be 87% and 82%,
respectively, based on the relative intensity of the labeled and
unlabeled protein peaks measured from MS.
Fluorescence Spectra. All fluorescence spectra were recorded on
a Cary Eclipse Fluorescence Spectrophotometer using a 0.70 mL
quartz cuvette under a fixed λEX of 595 nm over a range of 605−750
nm. All measurements were performed in a binding buffer (20 mM
HEPES, 100 mM NaCl, 10 mM CaCl2, pH 7.8) containing 1 mg/mL
of BSA to minimize any nonspecific absorption of the GNPs and
proteins on surfaces. For the apparent Kd measurement, the
concentrations of labeled DC-SIGN or DC-SIGNR protein and
GNP-glycans were varied simultaneously in a fixed protein/GNP
molar ratio of 1:1. The samples were incubated at RT for 20 min
before recording the fluorescence spectra. The fluorescence spectra of
the protein in the absence of the GNP-glycans, recorded under
identical experiment conditions, were used to determine the
quenching efficiency. The instrument PMT voltages were adjusted
to compensate the low fluorescence signals at low concentrations. The
quenching efficiency (QE) of DC-SIGN/R binding to each GNP-
glycan was calculated via eq 1, and the resulting QE-concentration
relationship was fitted by Hill’s equation (eq 2) to derive the apparent
binding Kd values.
Dynamic Light Scattering. The hydrodynamic diameters (Dh)
of wild-type DC-SIGN/R and GNP-glycans in pure water and in a
binding buffer (20 mM HEPES, 100 mM NaCl, 10 mM CaCl2, pH
7.8) were recorded on a Malvern ZETASizer-Nano using disposable
polystyrene cuvettes as reported in our previous papers.35,68 For
monitoring GNP-DiMan binding to wild-type DC-SIGN/R, a series
of samples, each containing GNP-DiMan (10 nM) and a varying
amount of wild-type DC-SIGN/R, were mixed in a binding buffer at
RT for 20 min before DLS measurement was carried out. Ten
consecutive scans were performed for each sample, and the resulting
volume Dh distribution histograms for each sample were combined
and fitted by Gaussian distributions to estimate their Dhs.
35
TEM Imaging. Three samples: (1) GNP-DiMan, (2) GNP-DiMan
+ wild-type DC-SIGN, and (3) GNP-DiMan + wild-type DC-SIGNR
were incubated (final CGNP = 40 nM and Cprotein = 1.5 μM) in a
binding buffer overnight. The samples were prepared by plunge-
freezing into liquid ethane followed by warming under vacuum to
capture the GNP dispersions in their native dispersed state as
demonstrated in our previous paper.63 Briefly, 3.5 μL of suspension
was placed onto a plasma-cleaned TEM grid with a continuous carbon
support film, blotted, and plunge frozen into liquid ethane. The TEM
grids were then warmed to RT over several minutes by placing the
specimens in the liquid nitrogen cooled storage container in a rotary
pumped vacuum desiccator.
The samples were then analyzed using an FEI Titan Themis 300
G2 S/TEM equipped with FEI SuperX energy dispersive X-ray
(EDX) spectrometers and a Gatan OneView CCD. Images were
collected for each sample, with EDX spectroscopy used to confirm
that the small nanoparticles imaged were indeed GNPs as Au species
were detected together with other peaks (carbon, oxygen, silicon, and
copper) due to the microscope, TEM grid, or support film. A series of
images at the same magnification were recorded for each sample,
allowing easy comparison of the nanoparticle dispersion state of the
three samples. The TEM images were analyzed automatically by
MATLAB scripts to derive the nearest neighbor distances (NNDs) as
reported previously.35
Virus Inhibition. The effects of GNP-glycans (glycan = Man,
DiMan, (Man)3, or (DiMan)3) on Ebola virus glyco-protein (EBOV-
GP) driven entry into 293T cells were assessed using our established
procedures.34,35 Briefly, 293T cells seeded in 96-well plates were
transfected with plasmids encoding DC-SIGN or DC-SIGNR or
control transfected with empty plasmid (pcDNA). The cells were
washed at 16 h post transfection and further cultivated at 37 °C, 5%
CO2 in Dulbecco’s modified eagle medium (DMEM) containing 10%
fetal bovine serum (FBS). At 48 h post transfection, the cells were
exposed to twice the final concentration of GNP-glycan inhibitor in
DMEM supplemented with 10% FBS for 30 min in a total volume of
50 μL. Thereafter, the resulting cells were inoculated with 50 μL of
preparations of MLV vector particles encoding the luciferase gene and
bearing either EBOV-GP (which can use DC-SIGN/R for
augmentation of host cell entry) or the vesicular stomatitis virus
glycoprotein (VSV-G, which cannot use DC-SIGN/R for augmenta-
tion of host cell entry). Under these conditions, binding of GNP-
glycan nanoparticles to 293T cell surface DC-SIGN/R receptors can
block EBOV-GP interactions with these lectin receptors, resulting in
reduced transduction efficiency of the virus particles and hence
reducing the cellular luciferase activity. At 6 h post inoculation, 100
μL of fresh DMEM culture medium was added and the cells
incubated for another 72 h. Thereafter, luciferase activities in cell
lysates were determined using a commercially available kit (PJK),
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